Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WEILY SOONG

NPI
1316981608
CMS profile
286379
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$93,885.24

259 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WEILY SOONG

NPI 1316981608 · CMS profile ID 286379

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316981608?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WEILY SOONG, NPI 1316981608, CMS profile ID 286379. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316981608?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). WEILY SOONG, NPI 1316981608, CMS profile ID 286379. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316981608?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
WEILY SOONG, NPI 1316981608, CMS profile ID 286379, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1316981608?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

259 matching records · $93,885.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 259 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 259.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $3,900.0010/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001598875 CMS
Genentech USA, Inc. $25.8610/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040596278 CMS
Teva Pharmaceuticals USA, Inc. $26.0310/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056767769 CMS
Takeda Pharmaceuticals U.S.A., Inc. $34.9510/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055615695 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3.4210/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055615701 CMS
GlaxoSmithKline, LLC. $11.1710/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001599443 CMS
Regeneron Healthcare Solutions, Inc. $21.2310/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999458719 CMS
PFIZER INC. $19.3510/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050290477 CMS
GlaxoSmithKline, LLC. $13.3210/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001599991 CMS
AstraZeneca Pharmaceuticals LP $76.1609/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024985795 CMS
AstraZeneca Pharmaceuticals LP $60.5009/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025004229 CMS
AstraZeneca Pharmaceuticals LP $134.7109/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024983615 CMS
AstraZeneca Pharmaceuticals LP $659.4809/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025002249 CMS
AstraZeneca Pharmaceuticals LP $194.7709/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025028977 CMS
AstraZeneca Pharmaceuticals LP $265.7509/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025034188 CMS
AstraZeneca Pharmaceuticals LP $127.6409/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025023473 CMS
AstraZeneca Pharmaceuticals LP $56.9609/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025025773 CMS
Blueprint Medicines Corporation $16.4109/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051256367 CMS
Genentech USA, Inc. $22.4209/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040596223 CMS
Genentech USA, Inc. $30.3209/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040596219 CMS
Genentech USA, Inc. $25.9909/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040596265 CMS
LEO Pharma Inc. $18.4409/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053532733 CMS
Merck Sharp & Dohme LLC $13.6209/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048647081 CMS
AbbVie Inc. $13.9509/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073203 CMS
AbbVie Inc. $3,500.0009/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073199 CMS
Novartis Pharmaceuticals Corporation $14.0109/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257923 CMS
Amgen Inc. $1,850.0009/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020195369 CMS
AstraZeneca Pharmaceuticals LP $1,850.0009/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025024905 CMS
GlaxoSmithKline, LLC. $119.9709/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001598124 CMS
Novartis Pharmaceuticals Corporation $1.0509/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257917 CMS
AbbVie Inc. $25.8509/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073169 CMS
AbbVie Inc. $31.0509/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073175 CMS
AbbVie Inc. $361.8009/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073183 CMS
AbbVie Inc. $155.8309/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073189 CMS
AbbVie Inc. $874.3509/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073195 CMS
AbbVie Inc. $199.0209/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073159 CMS
AbbVie Inc. $163.8509/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073163 CMS
Optinose US, Inc. $18.7709/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035097769 CMS
AstraZeneca Pharmaceuticals LP $6,161.2509/05/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025002697 CMS
AstraZeneca Pharmaceuticals LP $18.9609/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024998811 CMS
AstraZeneca Pharmaceuticals LP $15.7209/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025014683 CMS
AstraZeneca Pharmaceuticals LP $45.0009/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025019777 CMS
PFIZER INC. $15.3409/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050023061 CMS
Amgen Inc. $125.0008/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020195365 CMS
AstraZeneca Pharmaceuticals LP $125.0008/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025057811 CMS
GENZYME CORPORATION $23.8008/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049939567 CMS
AbbVie Inc. $2,500.0008/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073151 CMS
AbbVie Inc. $10.5208/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073155 CMS
PFIZER INC. $19.2608/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049961381 CMS
AbbVie Inc. $124.9908/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073143 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $60,197.63 242
PY2020 $58,034.08 177
PY2021 $98,928.64 184
PY2022 $86,320.80 211
PY2023 $93,885.24 259
PY2024 $159,699.87 316
PY2025 $144,339.78 316

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,970.55 2
PY2025 Principal investigator $536,363.96 267
PY2024 Recipient $428.00 2
PY2024 Principal investigator $649,845.66 342
PY2023 Recipient $3,077.41 5
PY2023 Principal investigator $340,262.11 133
PY2022 Recipient $21,729.66 15
PY2022 Principal investigator $328,811.41 129
PY2021 Recipient $13,581.28 16
PY2021 Principal investigator $792,044.99 199
PY2020 Recipient $44,172.37 14
PY2020 Principal investigator $1,149,340.73 231
PY2019 Recipient $135,778.06 80
PY2019 Principal investigator $968,608.31 161

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

269 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,927.20 12/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240517349
Principal investigator 1 SANOFI US SERVICES INC. $15,097.00 12/22/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226136517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 12/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184279016
Principal investigator 1 PFIZER INC. $500.00 12/16/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228815666
Principal investigator 1 ABBVIE INC. $1,500.00 12/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202530504
Principal investigator 1 Incyte Corporation $176.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240517362
Principal investigator 1 Incyte Corporation $73.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240517422
Principal investigator 1 Incyte Corporation $11.95 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240517435
Principal investigator 1 Incyte Corporation $50.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240517469
Principal investigator 1 Incyte Corporation $5,000.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240517474
Principal investigator 1 Incyte Corporation $232.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240517478
Principal investigator 1 SANOFI US SERVICES INC. $500.00 12/08/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226136481
Principal investigator 1 SANOFI US SERVICES INC. $500.00 12/08/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136497
Principal investigator 1 Incyte Corporation $3,166.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240517390
Principal investigator 1 Incyte Corporation $1,450.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240517445
Principal investigator 1 GlaxoSmithKline, LLC. $7,297.43 12/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192156872
Principal investigator 1 GlaxoSmithKline, LLC. $3,564.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192156877
Principal investigator 1 Incyte Corporation $80.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517413
Principal investigator 1 Incyte Corporation $135.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12.70 11/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184264503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.71 11/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184264505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.40 11/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184264507
Principal investigator 1 SANOFI US SERVICES INC. $358.80 11/17/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136460
Principal investigator 1 SANOFI US SERVICES INC. $15,496.00 11/17/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136463
Principal investigator 1 Incyte Corporation $20.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517353
Principal investigator 1 Incyte Corporation $6.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517357
Principal investigator 1 Incyte Corporation $40.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517366
Principal investigator 1 Incyte Corporation $169.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517369
Principal investigator 1 Incyte Corporation $169.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517374
Principal investigator 1 Incyte Corporation $80.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517378
Principal investigator 1 Incyte Corporation $80.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517382
Principal investigator 1 Incyte Corporation $80.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517387
Principal investigator 1 Incyte Corporation $322.20 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517395
Principal investigator 1 Incyte Corporation $135.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517399
Principal investigator 1 Incyte Corporation $90.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517404
Principal investigator 1 Incyte Corporation $240.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517408
Principal investigator 1 Incyte Corporation $180.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517417
Principal investigator 1 Incyte Corporation $128.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517430
Principal investigator 1 Incyte Corporation $200.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517440
Principal investigator 1 Incyte Corporation $500.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517449
Principal investigator 1 Incyte Corporation $500.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517453
Principal investigator 1 Incyte Corporation $500.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517458
Principal investigator 1 Incyte Corporation $202.50 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517462
Principal investigator 1 Incyte Corporation $120.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517465
Principal investigator 1 Incyte Corporation $45.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517482
Principal investigator 1 Incyte Corporation $45.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517486
Principal investigator 1 Incyte Corporation $45.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517489
Principal investigator 1 Incyte Corporation $45.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517493
Principal investigator 1 Incyte Corporation $68.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517497
Principal investigator 1 Incyte Corporation $60.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517500
Principal investigator 1 Incyte Corporation $60.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517505
Principal investigator 1 Incyte Corporation $60.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517509
Principal investigator 1 ABBVIE INC. $1,313.55 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202522873
Principal investigator 1 ABBVIE INC. $80.00 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202522935
Principal investigator 1 ABBVIE INC. $3,300.00 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202522937
Principal investigator 1 ABBVIE INC. $25.00 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202522939
Principal investigator 1 ABBVIE INC. $433.00 11/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202521087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $409.93 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252586
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.90 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252588
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $264.82 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.07 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $529.03 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $227.71 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.80 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $263.88 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.71 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.47 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $789.26 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,238.92 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252608
Principal investigator 1 SANOFI US SERVICES INC. $2,310.00 10/20/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136436
Principal investigator 1 SANOFI US SERVICES INC. $1,978.00 10/14/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 10/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184249847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 10/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184249849
Principal investigator 1 ABBVIE INC. $392.00 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202514267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,238.92 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184248952
Principal investigator 1 PFIZER INC. $500.00 10/03/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228825601
Principal investigator 1 SANOFI US SERVICES INC. $60.00 09/29/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136402
Principal investigator 1 PFIZER INC. $1,273.14 09/24/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228835544
Recipient Amgen Inc. $2,030.55 09/22/2025 Covered Recipient Physician A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE) No dispute reported 06/30/2026 1246636938
Principal investigator 1 SANOFI US SERVICES INC. $770.00 09/15/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136348
Principal investigator 1 SANOFI US SERVICES INC. $1,465.50 09/15/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136388
Principal investigator 1 SANOFI US SERVICES INC. $10,858.00 09/15/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136393
Principal investigator 1 SANOFI US SERVICES INC. $445.00 09/15/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136399
Principal investigator 1 Incyte Corporation $20.00 09/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517315
Principal investigator 1 Incyte Corporation $10.00 09/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $185.42 09/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184235165
Principal investigator 1 SANOFI US SERVICES INC. $120.00 09/03/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136345
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 09/03/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136352
Principal investigator 1 SANOFI US SERVICES INC. $235.00 09/03/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136357
Principal investigator 1 SANOFI US SERVICES INC. $327.60 09/03/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136367
Principal investigator 1 SANOFI US SERVICES INC. $19,681.00 08/25/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226136383
Principal investigator 1 Incyte Corporation $1,312.20 08/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517329
Principal investigator 1 SANOFI US SERVICES INC. $700.00 08/11/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136334
Principal investigator 1 SANOFI US SERVICES INC. $10,892.00 08/11/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136342
Principal investigator 1 ABBVIE INC. $2,310.20 08/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501632
Principal investigator 1 PFIZER INC. $3,216.10 08/05/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228844208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184217481
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 07/18/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049611
Principal investigator 1 ABBVIE INC. $245.00 07/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202498708
Principal investigator 1 SANOFI US SERVICES INC. $53,200.70 07/14/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136275
Principal investigator 1 ABBVIE INC. $433.00 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202495885
Principal investigator 1 Incyte Corporation $60.00 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517319
Principal investigator 1 Incyte Corporation $20.00 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517323
Principal investigator 1 Incyte Corporation $169.00 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517337
Principal investigator 1 Incyte Corporation $80.00 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517340
Principal investigator 1 Incyte Corporation $94.50 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517344
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.53 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.53 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212487
Principal investigator 1 SANOFI US SERVICES INC. $140.00 07/02/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136312
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,488.18 07/01/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190310446
Principal investigator 1 PFIZER INC. $2,256.59 06/26/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228851666
Principal investigator 1 Incyte Corporation $1,970.00 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517278
Principal investigator 1 Incyte Corporation $1,115.20 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517307
Principal investigator 1 Eli Lilly and Company $20,725.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CTR OF ALABAMA, LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187879125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184206813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184206815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184206819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184206821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184206823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184206825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184206827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184206829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184206833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184206835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.00 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207585
Principal investigator 1 SANOFI US SERVICES INC. $320.00 06/16/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136268
Principal investigator 1 PFIZER INC. $1,600.00 05/30/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228857238
Principal investigator 1 PFIZER INC. $1,883.31 05/29/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228857294
Principal investigator 1 SANOFI US SERVICES INC. $1,240.00 05/27/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136265
Principal investigator 1 PFIZER INC. $1,571.50 05/14/2025 Non-covered Recipient Entity
Clinical Research Center of Alabama
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228857231
Principal investigator 1 Incyte Corporation $1,283.40 05/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517291
Principal investigator 1 ABBVIE INC. $1,073.70 05/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202482141
Principal investigator 1 PFIZER INC. $1,881.59 05/06/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228857222
Principal investigator 1 SANOFI US SERVICES INC. $140.00 05/05/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226136206
Principal investigator 1 SANOFI US SERVICES INC. $45.00 05/05/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226136210
Principal investigator 1 SANOFI US SERVICES INC. $3,654.90 05/05/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.53 04/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190235
Principal investigator 1 SANOFI US SERVICES INC. $1,285.00 04/28/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136224
Principal investigator 1 SANOFI US SERVICES INC. $360.00 04/28/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136228
Principal investigator 1 SANOFI US SERVICES INC. $193.00 04/28/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136232
Principal investigator 1 ABBVIE INC. $225.00 04/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202478930
Principal investigator 1 ABBVIE INC. $500.00 04/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202478934
Principal investigator 1 Incyte Corporation $2,000.00 04/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240517258
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,110.00 04/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA No dispute reported 06/30/2026 1185554799
Principal investigator 1 Eli Lilly and Company $231.30 04/23/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187892824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.00 04/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184184788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184184790
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,250.00 04/17/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049613
Principal investigator 1 Incyte Corporation $972.60 04/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517269
Principal investigator 1 Incyte Corporation $1,426.00 04/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517283
Principal investigator 1 Incyte Corporation $1,970.00 04/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517287
Principal investigator 1 PFIZER INC. $25.00 04/08/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228859841
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 04/08/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049641
Principal investigator 1 Eli Lilly and Company $4,000.00 04/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CTR OF ALABAMA, LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 3 EFFICACY AND SAFETY STUDY OF LEBRIKIZUMAB/ LY3650150 IN ADULTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS ON A BACKGROUND THERAPY WITH INTRANASAL CORTICOSTEROIDS No dispute reported 06/30/2026 1187875773
Principal investigator 1 Incyte Corporation $21.12 04/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517274
Principal investigator 1 Incyte Corporation $1.96 04/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517295
Principal investigator 1 Incyte Corporation $1.92 04/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517299
Principal investigator 1 Incyte Corporation $57.25 04/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517303
Principal investigator 1 Incyte Corporation $32.36 04/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517311
Principal investigator 1 SANOFI US SERVICES INC. $10,522.20 04/02/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136168
Principal investigator 1 SANOFI US SERVICES INC. $12,364.50 03/24/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136156
Principal investigator 1 PFIZER INC. $4,026.00 03/22/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228862367
Principal investigator 1 SANOFI US SERVICES INC. $5,236.50 03/17/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136196
Principal investigator 1 Incyte Corporation $990.00 03/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517090
Principal investigator 1 Incyte Corporation $1,458.00 03/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517098
Principal investigator 1 Incyte Corporation $1,476.00 03/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517109
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $60.00 03/13/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049615
Principal investigator 1 Incyte Corporation $50.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517040
Principal investigator 1 Incyte Corporation $36.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517045
Principal investigator 1 Incyte Corporation $20.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517050
Principal investigator 1 Incyte Corporation $90.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517053
Principal investigator 1 Incyte Corporation $80.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517057
Principal investigator 1 Incyte Corporation $40.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517075
Principal investigator 1 Incyte Corporation $10.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517083
Principal investigator 1 Incyte Corporation $18.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517088
Principal investigator 1 Incyte Corporation $94.50 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517105
Principal investigator 1 Incyte Corporation $180.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517113
Principal investigator 1 Incyte Corporation $100.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517122
Principal investigator 1 Incyte Corporation $127.56 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517125
Principal investigator 1 Incyte Corporation $169.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517129
Principal investigator 1 Incyte Corporation $45.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517134
Principal investigator 1 Incyte Corporation $45.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517139
Principal investigator 1 Incyte Corporation $72.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517144
Principal investigator 1 Incyte Corporation $40.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517148
Principal investigator 1 Incyte Corporation $180.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517152
Principal investigator 1 Incyte Corporation $180.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517156
Principal investigator 1 Incyte Corporation $152.10 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517221
Principal investigator 1 Incyte Corporation $100.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517229
Principal investigator 1 Incyte Corporation $100.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517234
Principal investigator 1 Incyte Corporation $40.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517244
Principal investigator 1 Incyte Corporation $512.50 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240517036
Principal investigator 1 SANOFI US SERVICES INC. $15,417.90 03/04/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226136192
Principal investigator 1 Incyte Corporation $11.45 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517199
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,873.82 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy No dispute reported 06/30/2026 1190303283
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/24/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049639
Principal investigator 1 Incyte Corporation $500.00 02/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240517513
Principal investigator 1 Incyte Corporation $1,426.00 02/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517078
Principal investigator 1 Incyte Corporation $1,250.60 02/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517094
Principal investigator 1 Incyte Corporation $1,426.00 02/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517116
Principal investigator 1 Incyte Corporation $1,970.00 02/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517225
Principal investigator 1 Incyte Corporation $1,554.00 02/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517240
Principal investigator 1 Eli Lilly and Company $14,549.00 02/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CTR OF ALABAMA, LLC
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187878239
Principal investigator 1 SANOFI US SERVICES INC. $600.00 02/18/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136164
Principal investigator 1 SANOFI US SERVICES INC. $16,534.00 02/18/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226136188
Principal investigator 1 Incyte Corporation $548.08 02/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240517266
Principal investigator 1 ABBVIE INC. $4,110.40 02/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202445381
Principal investigator 1 PFIZER INC. $13,570.28 02/05/2025 Non-covered Recipient Entity
AllerVie Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228835514
Recipient PFIZER INC. $940.00 01/28/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228821645
Principal investigator 1 Eli Lilly and Company $48.13 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CTR OF ALABAMA, LLC
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187879123
Principal investigator 1 Incyte Corporation $4,891.26 01/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240517262
Principal investigator 1 SANOFI US SERVICES INC. $13,847.70 01/21/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136140
Principal investigator 1 Incyte Corporation $1,554.00 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517061
Principal investigator 1 Incyte Corporation $1,476.00 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517067
Principal investigator 1 Incyte Corporation $2,098.00 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517071
Principal investigator 1 Incyte Corporation $1,104.80 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517102
Principal investigator 1 Incyte Corporation $1,554.00 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $978.94 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184148107
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,064.80 01/16/2025 Non-covered Recipient Entity
ALLERVIE HEALTH
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185554803
Principal investigator 1 PFIZER INC. $1,000.00 01/15/2025 Non-covered Recipient Entity
Clinical Research Center of Alabama
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228862692
Principal investigator 1 Incyte Corporation $46.60 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501644
Principal investigator 1 Incyte Corporation $11.40 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501649
Principal investigator 1 Incyte Corporation $98.98 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501652
Principal investigator 1 Incyte Corporation $9.18 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501656
Principal investigator 1 Incyte Corporation $6.60 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501659
Principal investigator 1 Incyte Corporation $12.96 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501664
Principal investigator 1 Incyte Corporation $2.40 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501668
Principal investigator 1 Incyte Corporation $74.64 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501673
Principal investigator 1 Incyte Corporation $18.64 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501678
Principal investigator 1 Incyte Corporation $12.12 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501682
Principal investigator 1 Incyte Corporation $16.31 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501685
Principal investigator 1 Incyte Corporation $3.00 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501689
Principal investigator 1 Incyte Corporation $149.28 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501693
Principal investigator 1 Incyte Corporation $32.62 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501698
Principal investigator 1 Incyte Corporation $74.64 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501701
Principal investigator 1 Incyte Corporation $37.32 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501705
Principal investigator 1 Incyte Corporation $2.16 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501709
Principal investigator 1 Incyte Corporation $1.20 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501713
Principal investigator 1 Incyte Corporation $4.66 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501717
Principal investigator 1 Incyte Corporation $6.99 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501720
Principal investigator 1 Incyte Corporation $52.48 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501724
Principal investigator 1 Incyte Corporation $279.90 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501729
Principal investigator 1 Incyte Corporation $4.20 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501733
Principal investigator 1 Incyte Corporation $5.40 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501737
Principal investigator 1 Incyte Corporation $5.40 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501740
Principal investigator 1 Incyte Corporation $5.40 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501744
Principal investigator 1 Incyte Corporation $4.32 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501748
Principal investigator 1 Incyte Corporation $52.48 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501752
Principal investigator 1 Incyte Corporation $52.48 01/09/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240501755
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 01/09/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049617
Principal investigator 1 AstraZeneca Pharmaceuticals LP $52,813.40 01/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Multicentre,Randomised,Double Blind,Parallel Group,Placebo Controlled,52 week,Phase 3,Efficacy and Safety Study of Tezepelumab in 5 to 12 Year Old Children with Severe Uncontrolled Asthma HORIZON No dispute reported 06/30/2026 1185554801
Principal investigator 1 Incyte Corporation $80.15 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517162
Principal investigator 1 Incyte Corporation $49.36 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517166
Principal investigator 1 Incyte Corporation $32.36 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517170
Principal investigator 1 Incyte Corporation $9.80 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517175
Principal investigator 1 Incyte Corporation $115.70 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517179
Principal investigator 1 Incyte Corporation $48.00 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517184
Principal investigator 1 Incyte Corporation $99.12 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517188
Principal investigator 1 Incyte Corporation $15.26 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517191
Principal investigator 1 Incyte Corporation $15.26 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517195
Principal investigator 1 Incyte Corporation $15.26 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517203
Principal investigator 1 Incyte Corporation $24.78 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517207
Principal investigator 1 Incyte Corporation $13.44 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517211
Principal investigator 1 Incyte Corporation $13.44 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517214
Principal investigator 1 Incyte Corporation $4.80 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517218
Principal investigator 1 Incyte Corporation $15.26 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240517253
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,656.30 01/01/2025 Non-covered Recipient Entity
ALABAMA ALLERGY AND ASTHMA CENTER
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy No dispute reported 06/30/2026 1190308336